Manifestaciones cardiovasculares de la enfermedad de Parkinson: revisión de la literatura

Natalia Henao Piedrahita; Sebastián Pérez Correa; Santiago Vásquez Builes; Gustavo Adolfo Díaz Silva

doi:10.22379/24224022374

Vol. 37 No. 2 (2021), Review

Vol. 37 No. 2 (2021)

Cardiovascular manifestations of Parkinson's disease: literature review

Review

https://doi.org/10.22379/24224022374

Published 2021-07-08

Natalia Henao Piedrahita⁺⁻
Sebastián Pérez Correa⁺⁻
Santiago Vásquez Builes⁺⁻
Gustavo Adolfo Díaz Silva⁺⁻

Natalia Henao Piedrahita

Médico, residente de medicina interna, Universidad Pontificia Bolivariana. Medellín, Antioquia, Colombia.

Sebastián Pérez Correa

Médico general, Universidad CES. Medellín, Antioquia, Colombia.

Santiago Vásquez Builes

Médico, residente de Neurología, Universidad CES, Instituto Neurológico De Colombia. Medellín, Antioquia, Colombia. Miembro del semillero de neurociencias CES. Medellín, Antioquia, Colombia.

Gustavo Adolfo Díaz Silva

Neurólogo clínico, universidad CES, Instituto Neurológico De Colombia. Medellín, Antioquia, Colombia. Epidemiólogo clínico, Universidad CES. Medellín, Antioquia, Colombia. Director del semillero de neurociencias CES. Medellín, Antioquia, Colombia.

PDF (Español)

XML (Español)

Keywords

Parkinson's disease
dysautonomia
orthostatic hypotension
heart failure
hypertension.(MeSH)

Abstract

Parkinson's disease is the second most prevalent neurodegenerative disease in the world and is characterized by bradykinesia, tremor, rigidity, and postural instability. Although it has been considered as a motor system disease, it is currently considered as a complex neurological disease with different motor, non-motor, and autonomic manifestations. Cardiovascular manifestations in patients with Parkinson's disease are frequent and they have a great impact on quality of life. This article seeks to carry out a narrative review of the pathophysiological mechanisms and the main cardiovascular clinical manifestations in patients with Parkinson's disease.

https://doi.org/10.22379/24224022374

PDF (Español)

XML (Español)

References

Hayes M. Parkinson's disease and parkinsonism. Am J Med. 2019; 132(7):802-7. DOI: 10.1016/j.amjmed.2019.03.001.

Palacios-Sánchez L, Torres M, Botero-Meneses J. James Parkinson and his essay on "shaking palsy", two hundred years later. Arq Neuropsiquiatr. 2017; 75(9):671-2. DOI: 10.1590/0004-282X20170108.

Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014;14(5):310-22. doi: 10.1136/practneurol-2013-000741.

Merola A, Romagnolo A, Rosso M, Suri R, Berndt Z, Maule S, et al. Autonomic dysfunction in Parkinson's disease: a prospective cohort study. Mov Disord. 2018;33(3):391-397. doi: 10.1002/mds.27268.

Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7):435-50. DOI: 10.1038/nrn.2017.62.

Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello T et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009; 24(11):1641-9. DOI: 10.1002/mds.22643.

Gulunay A, Cakmakli G, Yon M, Ulusoy E, Karakoc M. Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series. Psychogeriatrics. 2020; 20(2):206-11. DOI: 10.1111/psyg.12489.

Prasuhn J, Piskol L, Vollstedt E, Graf J, Schmidt A, Tadic V et al. Non-motor symptoms and quality of life in subjects with mild parkinsonian signs. Acta Neurol Scand. 2017; 136(5):495-500. DOI: 10.1111/ane.12760.

Rodríguez-Violante M, Ospina-García N, Dávila-Avila N, Cruz-Fino D, Cruz-Landero A, Cervantes-Arriaga A. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease. Arq Neuropsiquiatr. 2018; 76(8):517-21. DOI: 10.1590/0004-282X20180074.

Piqueras-Flores J, López-García A, Moreno-Reig A, González-Martínez A, Hernández-González A, Vaamonde-Gamo J et al. Structural and functional alterations of the heart in Parkinson's disease. Neurol Res. 2018; 40(1):53-61. DOI: 10.1080/01616412.2017.1390933.

Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C. Understanding the links between cardiovascular disease and Parkinson's disease. Mov Disord. 2020; 35(1):55-74. DOI: 10.1002/mds.27836.

Goldstein D, Holmes C, Li S, Bruce S, Metman L, Cannon R. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000; 133(5):338-47. DOI: 10.7326/0003-4819133-5-200009050-00009.

Goldstein D, Holmes C, Lopez G, Wu T, Sharabi Y. Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord. 2018; 52:90-3. DOI: 10.1016/j.parkreldis.2017.10.003.

Coon E, Cutsforth-Gregory J, Benarroch E. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018; 33(3):349-58. DOI: 10.1002/mds.27186.

Metzger J, Emborg M. Autonomic dysfunction in Parkinson disease and animal models. Clin Auton Res. 2019; 29(4):397-414. DOI: 10.1007/s10286-018-00584-7.

Mendoza-Velasquez J, Flores-Vazquez J, Barron-Velazquez E, Sosa-Ortiz AL, Illigens B, Siepmann T. Autonomic dysfunction in ?-synucleinopathies. Front Neurol. 2019; 10:363. DOI: 10.3389/fneur.2019.00363.

Mollenhauer B, Zimmermann J, SixeEDoring F, Focke N, Wicke T, Ebentheuer J et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord. 2019; 34(1):67-77. DOI: 10.1002/mds.27492.

Andican G, Konukoglu D, Bozluolcay M, Bayulkem K, Firtiina S, Burcak G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol Belg. 2012; 112(2):155-9. DOI: 10.1007/s13760-012-0015-3.

Huebecker M, Moloney E, Van der Spoel A, Priestman D, Isacson O, Hallett P et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019; 14(1):40. DOI: 10.1186/s13024-019-0339-z.

Taguchi Y, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J et al. Glucosylsphingosine promotes a-synuclein pathology in mutant GBA-associated Parkinson's disease. J Neurosci. 2017; 37(40):9617-31. DOI: 10.1523/JNEUROSCI.1525-17.2017.

Alcalay R, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu R et al. SMPD1 mutations, activity, and a-synuclein accumulation in Parkinson's disease. Mov Disord. 2019; 34(4):526-35. DOI: 10.1002/mds.27642.

Guedes L, Chan R, Gomes M, Conceição V, Machado R, Soares T et al. Serum lipid alterations in GBA-associated Parkinson's disease. Parkinsonism Relat Disord. 2017; 44:58-65. DOI: 10.1016/j.parkreldis.2017.08.026.

Burbulla L, Song P, Mazzulli J, Zampese E, Wong Y, Jeon S et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017; 357(6357):1255-61. DOI: 10.1126/science.aam9080.

Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B et al. Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study. Mov Disord. 2018; 33(8):1298-305. DOI: 10.1002/mds.27413.

Huang X, Sterling N, Du G, Sun D, Stetter C, Kong L et al. Brain cholesterol metabolism and Parkinson's disease. Mov Disord. 2019; 34(3):386-95. DOI: 10.1002/mds.27609.

Sanjari H, Valitabar Z, Ashraf-Ganjouei A, Mojtahed M, Ghazi F, Hadi M. Cerebrospinal fluid C-reactive protein in Parkinson's disease: associations with motor and non-motor symptoms. NeuroMolecular Med. 2018; 20(3):376-85. DOI: 10.1007/s12017-018-8499-5.

Park J, Kim D, Park Y, Kwon D, Choi M, Jung J, Han K. Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: a nationwide, population-based cohort study. Circulation. 2020; 141(14):1205-7. DOI: 10.1161/CIRCULATIONAHA.119.044948.

Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in Parkinson's disease: does it matter if asymptomatic? Parkinsonism Relat Disord 2016;33:65-71.

Scorza F, Fiorini A, Scorza C, Finsterer J. Cardiac abnormalities in Parkinson's disease and Parkinsonism. J Clin Neurosci. 2018; 53:1-5. DOI: 10.1016/j.jocn.2018.04.031.

Fanciulli A, Campese N, Goebel G, Ndayisaba J, Eschlboeck S, Kaindlstorfer C et al. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020; 95(21):e2854-65. DOI: 10.1212/WNL.0000000000010749.

Allcock L, Ullyart K, Kenny R, Burn D. Frequency of ortho-static hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75(10):1470-1. DOI: 10.1136/jnnp.2003.029413.

Goldstein D. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res. 2006; 16(1):46-54. DOI: 10.1007/s10286-006-0317-8.

Goldstein D, Eldadah B, Holmes C, Pechnik S, Moak J, Saleem A et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005; 46(6):1333-9. DOI: 10.1161/01.HYP.0000188052.69549.e4.

Hiorth Y, Pedersen K, Dalen I, Tysnes O, Alves G. Ortho-static hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology. 2019; 93(16):e1526-34. DOI: 10.1212/WNL.0000000000008314.

Li L, Guo P, Ding D, Lian T, Zuo L, Du F et al. Parkinson's disease with orthostatic hypotension: analyses of clinical characteristics and influencing factors. Neurol Res. 2019; 41(8):734-741. DOI: 10.1080/01616412.2019.1610224.

Arbogast S, Alshekhlee A, Hussain Z, McNeeley K, Chelimsky T. Hypotension unawareness in profound orthostatic hypotension. Am J Med. 2009; 122(6):574-80. DOI: 10.1016/j.amjmed.2008.10.040.

Strano S, Fanciulli A, Rizzo M, Marinelli P, Palange P, Tiple D et al. Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. J Neurol Sci. 2016; 370:251-5. DOI: 10.1016/j.jns.2016.09.036.

Longardner K, Bayram E, Litvan I. Orthostatic hypotension is associated with cognitive decline in Parkinson disease. Front Neurol. 2020;11:897. doi: 10.3389/fneur.2020.00897.

Pfeiffer R. Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother. 2012; 12(6):697-706. DOI: 10.1586/ern.12.17.

Rueda M, Castro F. Disfunción autonómica en la enfermedad de Parkinson: enfoque práctico. Acta Neurol Colomb. 2019; 35(S1): 69-74. DOI: 10.22379/24224022252.

Suárez-Moro R, Castaño-García B. Trastornos cardiovasculares en la enfermedad de Parkinson. Rev Neurol. 2010; 50(S02):59. DOI: 10.33588/rn.50S02.2009741.

Umehara T, Nakahara A, Matsuno H, Toyoda C, Oka H. Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease. J Neural Transm. 2016; 123(11):1331-9. DOI: 10.1007/s00702-016-1594-6.

Km J, Lee S, Oh Y, Park J, An J, Park S, et al. Cardiovascular autonomic dysfunction in mild and advanced Parkinson's disease. J Mov Disord. 2016; 9(2):97-103. DOI: 10.14802/jmd.16001.

Mokwatsi G, Schutte A, Mels C, Kruger R. Morning blood pressure surge relates to autonomic neural activity in young non-dipping adults: The african-PREDICT study. Hear Lung Circ. 2018; 28(8):1197-205. DOI: 10.1016/j.hlc.2018.07.003.

Sommer S, Aral-Becher B, Jost W Nondipping in Parkinson's disease. Parkinsons Dis. 2011; 2011:897586. DOI: 10.4061/2011/897586.

Gibbons C, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017; 264(8):1567-82. DOI: 10.1007/s00415-016-8375-x.

Fanciulli A, Góbel G, Ndayisaba J, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res. 2016; 26(2):97-105. DOI: 10.1007/s10286-015-0336-4.

Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016;26(1):15-21. DOI: 10.1007/s10286-015-0324-8.

Espay A, LeWitt P, Hauser R, Merola A, Masellis M, Lang A. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisa-tion of treatment targets. Lancet Neurol. 2016 ;15(9):954-66. DOI: 10.1016/S1474-4422(16)30079-5.

Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson's disease. Expert Rev Neurother. 2015; 15(10):1189-203. DOI: 10.1586/14737175.2015.1095093.

Baldacci F, Vergallo A, Del Dotto P, Ulivi M, Palombo C, Casolo G, et al. Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. Parkinsonism Relat Disord. 2014; 20(11):1313-4. DOI: 10.1016/j.parkreldis.2014.09.009.

Lazaros G, Dimitriadis K, Xanthopoulou M, Latsios G, Antoniou C, Lazarou E, et al. Takotsubo cardiomyopathy and Parkinson's disease: an exceptionally uncommon clinical duet. Hellenic J Cardiol. 2019; 60(5):334-5. DOI: 10.1016/j.hjc.2018.12.002.

Santoro F, Carapelle E, Cieza S, Musaico F, Ferraretti A, D'Orsi G, et al. Potential links between neurological disease and Tako-Tsubo cardiomyopathy: a literature review. Int J Cardiol. 2013; 168(2):688-91. DOI: 10.1016/j.ijcard.2013.03.093.

De Pablo-Fernandez E, Tur C, Revesz T, Lees A, Holton J, Warner T. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 2017; 74(8):970-6. DOI: 10.1001/jamaneurol.2017.1125.

Kim B, Lim Y, Lee H, Lee J, Kim K, Kim S, et al. Non-dipper pattern is a determinant of the inappropriateness of left ventricular mass in essential hypertensive patients. Korean Circ J. 2011; 41(4):191. DOI: 10.4070/kcj.2011.41.4.191.

Tsukamoto T, Kitano Y, Kuno S. Blood pressure fluctuation and hypertension in patients with Parkinson's disease. Brain Behav. 2013; 3(6):710-4. DOI: 10.1002/brb3.179.

Li Q, Wang C, Tang H, Chen S, Ma J. Stroke and coronary artery disease are associated with Parkinson's disease. Can J Neurol Sci. 2018; 45(5):559-65. DOI: 10.1017/cjn.2018.56.

Kitamura Y, Watanabe S, Taguchi M, Takagi K, Kawata T, Takahashi-Niki K, et al. Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats. Mol Neurodegener. 2011; 6(1):48. DOI: 10.1186/1750-1326-6-48.

Dongworth R, Mukherjee U, Hall A, Astin R, Ong S-B, Yao Z, et al. DJ-1 protects against cell death following acute cardiac ischemia-reperfusion injury. Cell Death Dis. 2014; 5(2):e1082-e1082. DOI: 10.1038/cddis.2014.41.

Mochizuki H, Ebihara Y, Ugawa Y, Ishii N, Taniguchi A, Nagamachi S, et al. PR prolongation and cardiac 123I-MIBG uptake reduction in Parkinson's disease. Eur Neurol. 2015; 74(1-2):107-11. DOI: 10.1159/000439022.

Cunnington AL, Hood K, White L. Outcomes of screening Parkinson's patients for QTc prolongation. Parkinsonism Relat Disord. 2013; 19(11):1000-3. DOI: 10.1016/j.parkrel-dis.2013.07.001.

Charron P, Genest M, Richard P, Komajda M, Pochmalicki G. A familial form of conduction defect related to a mutation in the PRKAG2 gene. EP Eur. 2007; 9(8):597-600. DOI: 10.1093/europace/eum071.

Bacchi S, Chim I, Kramer P, Postuma R. Domperidone for hypotension in Parkinson's disease: A systematic review. J Parkinsons Dis. 2017; 7(4):603-17. DOI: 10.3233/JPD-171209.

Renoux C, Dell'Anello S, Khairy P, Marras C, Bugden S, Turin T, et al. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol. 2016; 82(2):461-72. DOI: 10.1111/bcp.12964.

Nishida N, Yoshida K, Hata Y Sudden unexpected death in early Parkinson's disease: neurogenic or cardiac death? Cardiovasc Pathol. 2017; 30:19-22. DOI: 10.1016/j.carpath.2017.06.001.

Scorza F, Cavalheiro E, Scorza C, Ferraz H. Sudden unexpected death in Parkinson's disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilepsy Behav. 2016; 57:124-5. DOI: 10.1016/j.yebeh.2016.01.035.

Scorza F, Carmo A, Fiorini A, Nejm M, Scorza C, Finsterer J, et al. Sudden unexpected death in Parkinson's disease (SUDPAR): a review of publications since the decade of the brain. Clinics. 2017; 72(11):649-51. DOI: 10.6061/clinics/2017(11)01.

Moscovich M, Boschetti G, Moro A, Teive H, Hassan A, Munhoz R. Death certificate data and causes of death in patients with parkinsonism. Parkinsonism Relat Disord. 2017; 41:99-103. DOI: 10.1016/j.parkreldis.2017.05.022.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.